Lung Adenocarcinoma: From Genome Alterations to Therapeutic Discovery

肺腺癌:从基因组改变到治疗发现

基本信息

  • 批准号:
    10299281
  • 负责人:
  • 金额:
    $ 106.8万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-08-01 至 2028-07-31
  • 项目状态:
    未结题

项目摘要

Project Summary The introduction of new targeted therapies and immunotherapies has led to significant decreases in lung cancer mortality in the United States in recent years. However, lung cancer continues to kill over 135,000 Americans each year, and over a million people annually world-wide. Thus, there remains an urgent need to continue to improve the prevention, diagnosis and treatment of this deadly disease. Our research focuses on lung adenocarcinoma, the most common form of lung cancer. Lung adenocarcinoma is, at its root, a disease of the genome. The focus of my laboratory is to understand somatic genome alterations in human lung cancer, to use this understanding to elucidate lung cancer pathogenesis, and in turn to improve diagnosis and treatment. We have been honored to participate in many clinically impactful genomic discoveries, including the discoveries of BRAF and EGFR mutations that guide targeted therapy use. In recent work, we continue to advance knowledge of lung cancer genomes and their function. We described novel oncogenic mutations in lung cancer, the duplication of super-enhancer elements near known oncogenes. We analyzed the cancer-causing activity of lung adenocarcinoma mutated genes such as SOS1 and MGA; we initiated genomic approaches to immunological targets such as the ADAR RNA deaminase gene; and we generated a genomically engineered model of aneuploidy for lung cancer. Our proposed research falls into three broad categories: 1. Single gene alterations: we will analyze the mechanisms by which both mutations and copy number alterations underlie the pathogenesis of lung adenocarcinoma. Examples described in this proposal include the tumor suppressor gene CMTR2 and the lineage oncogene NKX2-1, which is the most significantly amplified gene in lung adenocarcinoma. 2. Immunological target identification: we will use genomic approaches to characterize immunological features of lung cancer and potential vulnerabilities. Examples shown here include continued studies of genes involved in RNA sensing & modification in the interferon pathway that are also cancer dependencies, as well as large-scale functional genomic screens to identify epitopes that are antigenic targets of T cells in lung cancer. 3. Genome-wide features. We continue to study aneuploidy and the function of gene dosage effects on cell growth and proliferation. In addition, we are developing a new approach for genome-based therapy: nucleic acid cleavage therapies that target the “neo-genome” in lung cancer DNA. This approach would exploit the novel genomic sequences that result from chromosomal rearrangements in cancer by using genome engineering tools to specifically target cancer cells. My goal is that the knowledge gained from the proposed research will deepen our understanding of human lung adenocarcinoma and will drive novel and effective treatments for lung cancer patients.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(2)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MATTHEW L. MEYERSON其他文献

MATTHEW L. MEYERSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MATTHEW L. MEYERSON', 18)}}的其他基金

How do genome alterations cause human lung cancer?
基因组改变如何导致人类肺癌?
  • 批准号:
    8955791
  • 财政年份:
    2015
  • 资助金额:
    $ 106.8万
  • 项目类别:
NKX2-1 Enhancer Amplification and Lineage Addiction in Lung Adenocarcinoma
肺腺癌中的 NKX2-1 增强子扩增和谱系成瘾
  • 批准号:
    10598959
  • 财政年份:
    2015
  • 资助金额:
    $ 106.8万
  • 项目类别:
Lung Adenocarcinoma: From Genome Alterations to Therapeutic Discovery
肺腺癌:从基因组改变到治疗发现
  • 批准号:
    10455040
  • 财政年份:
    2015
  • 资助金额:
    $ 106.8万
  • 项目类别:
How do genome alterations cause human lung cancer?
基因组改变如何导致人类肺癌?
  • 批准号:
    9118129
  • 财政年份:
    2015
  • 资助金额:
    $ 106.8万
  • 项目类别:
Lung Adenocarcinoma: From Genome Alterations to Therapeutic Discovery
肺腺癌:从基因组改变到治疗发现
  • 批准号:
    10683176
  • 财政年份:
    2015
  • 资助金额:
    $ 106.8万
  • 项目类别:
Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma
非小细胞肺癌的蛋白激酶治疗靶点
  • 批准号:
    8490596
  • 财政年份:
    2012
  • 资助金额:
    $ 106.8万
  • 项目类别:
Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma
非小细胞肺癌的蛋白激酶治疗靶点
  • 批准号:
    8660037
  • 财政年份:
    2012
  • 资助金额:
    $ 106.8万
  • 项目类别:
Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma
非小细胞肺癌的蛋白激酶治疗靶点
  • 批准号:
    8844212
  • 财政年份:
    2012
  • 资助金额:
    $ 106.8万
  • 项目类别:
Project 3: Targeting transcriptional mechanisms of therapeutic resistance in non-small cell lung cancer.
项目 3:针对非小细胞肺癌治疗耐药的转录机制。
  • 批准号:
    10231100
  • 财政年份:
    2012
  • 资助金额:
    $ 106.8万
  • 项目类别:
Core D: Program Administration
核心 D:项目管理
  • 批准号:
    10231105
  • 财政年份:
    2012
  • 资助金额:
    $ 106.8万
  • 项目类别:

相似海外基金

Elucidating the effects of extra chromosome elimination in mosaic aneuploidy syndromes: Pallister-Killian syndrome as a model
阐明额外染色体消除对嵌合非整倍体综合征的影响:以 Pallister-Killian 综合征为模型
  • 批准号:
    10887038
  • 财政年份:
    2023
  • 资助金额:
    $ 106.8万
  • 项目类别:
Characterization of aneuploidy, cell fate and mosaicism in early development
早期发育中非整倍性、细胞命运和嵌合体的表征
  • 批准号:
    10877239
  • 财政年份:
    2023
  • 资助金额:
    $ 106.8万
  • 项目类别:
The impact of aneuploidy on early human development
非整倍体对人类早期发育的影响
  • 批准号:
    MR/X007979/1
  • 财政年份:
    2023
  • 资助金额:
    $ 106.8万
  • 项目类别:
    Research Grant
Cell competition, aneuploidy, and aging
细胞竞争、非整倍性和衰老
  • 批准号:
    10648670
  • 财政年份:
    2023
  • 资助金额:
    $ 106.8万
  • 项目类别:
Understanding how aneuploidy disrupts quiescence in the model eukaryote Saccharomyces cerevisiae
了解非整倍体如何破坏模型真核生物酿酒酵母的静止状态
  • 批准号:
    10735074
  • 财政年份:
    2023
  • 资助金额:
    $ 106.8万
  • 项目类别:
Preventing Age-Associated Oocyte Aneuploidy: Mechanisms Behind the Drosophila melanogaster Centromere Effect
预防与年龄相关的卵母细胞非整倍性:果蝇着丝粒效应背后的机制
  • 批准号:
    10538074
  • 财政年份:
    2022
  • 资助金额:
    $ 106.8万
  • 项目类别:
Functional evaluation of kinesin gene variants associated with female subfertility and egg aneuploidy.
与女性生育力低下和卵子非整倍性相关的驱动蛋白基因变异的功能评估。
  • 批准号:
    10537275
  • 财政年份:
    2022
  • 资助金额:
    $ 106.8万
  • 项目类别:
Using CRISPR screening to uncover aneuploidy-specific genetic dependencies
使用 CRISPR 筛选揭示非整倍体特异性遗传依赖性
  • 批准号:
    10661533
  • 财政年份:
    2022
  • 资助金额:
    $ 106.8万
  • 项目类别:
Comparative Analysis of Aneuploidy and Cellular Fragmentation Dynamics in Mammalian Embryos
哺乳动物胚胎非整倍性和细胞破碎动力学的比较分析
  • 批准号:
    10366610
  • 财政年份:
    2022
  • 资助金额:
    $ 106.8万
  • 项目类别:
FASEB SRC: The Consequences of Aneuploidy: Honoring the Contributions of Angelika Amon
FASEB SRC:非整倍体的后果:纪念 Angelika Amon 的贡献
  • 批准号:
    10467260
  • 财政年份:
    2022
  • 资助金额:
    $ 106.8万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了